Compare FMC Corp (FMC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Twist Bioscience Corp — how do they compare? FMC Corp trades at $8.89 (market cap $1.41B), while Twist Bioscience Corp trades at $158.39 (market cap $10.32B). The key difference: Twist Bioscience Corp is far larger — about 7.3× FMC Corp's market cap, and FMC Corp pays a 3.52% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Twist Bioscience Corp for 27 Days on average.
| FMC | TWST | |
|---|---|---|
Market Cap | $1.41B | $10.32B |
Volume | 4,507,459 | 5,894,998 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $205.00 |
52-Week Low | $8.44 | $25.45 |
Typical Hold Time | 68 Days | 27 Days |
Enterprise Value | $5.22B | $10.24B |
Dividend Yield | 3.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.92, down 1.22% on the day, with a bearish technical signal and negative profitability metrics including a net income margin of -84.83% and ROE of -91.47% for 2025. Recent news highlights regulatory progress with rimisoxafen in Brazil and a minority equity investment from Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227.20M but driven by financing activities as operating cash flow was negative.
The outlook is challenged by significant losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include sustained negative margins, industry cyclicality, and execution of deleveraging plans. The stock presents a high-risk opportunity contingent on operational turnaround and debt reduction success.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
